Abstract

Before the advent of effective iron chelation, death from iron-induced cardiomyopathy occurred in the second decade in patients with transfusion-dependent chronic anemias. The advances in our understanding of iron metabolism; the ability to monitor iron loading in the liver, heart, pancreas and pituitary; and the availability of several effective iron chelators have dramatically improved survival and reduced morbidity from transfusion-related iron overload. Nevertheless, significantly increased survival brings about new complications such as malignant transformation resulting from prolonged exposure to iron, which need to be considered when developing long-term therapeutic strategies. This review discusses the current biology of iron homeostasis and its close relation to marrow activity in patients with transfusion-dependent anemias, and how biology informs clinical approach to treatment.

Bibliography

Bibliography
1.
Green
R
,
Charlton
R
,
Seftel
H
, et al
.
Body iron excretion in man: a collaborative study
.
Am J Med
.
1968
;
45
(
3
):
336
-
353
.
2.
Modell
B
,
Khan
M
,
Darlison
M
,
Westwood
MA
,
Ingram
D
,
Pennell
DJ
.
Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance
.
J Cardiovasc Magn Reson
.
2008
;
10
(
1
):
42
.
3.
Modell
B
,
Letsky
EA
,
Flynn
DM
,
Peto
R
,
Weatherall
DJ
.
Survival and desferrioxamine in thalassaemia major
.
Br Med J (Clin Res Ed)
.
1982
;
284
(
6322
):
1081
-
1084
.
4.
Coates
TD
,
Carson
S
,
Wood
JC
,
Berdoukas
V
.
Management of iron overload in hemoglobinopathies: what is the appropriate target iron level?
Ann N Y Acad Sci
.
2016
;
1368
(
1
):
95
-
106
.
5.
Angelucci
E
,
Brittenham
GM
,
McLaren
CE
, et al
.
Hepatic iron concentration and total body iron stores in thalassemia major
.
N Engl J Med
.
2000
;
343
(
5
):
327
-
331
.
6.
Anderson
LJ
,
Westwood
MA
,
Holden
S
, et al
.
Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance
.
Br J Haematol
.
2004
;
127
(
3
):
348
-
355
.
7.
Noetzli
LJ
,
Panigrahy
A
,
Mittelman
SD
, et al
.
Pituitary iron and volume predict hypogonadism in transfusional iron overload
.
Am J Hematol
.
2012
;
87
(
2
):
167
-
171
.
8.
Coates
TD
.
Physiology and pathophysiology of iron in hemoglobin-associated diseases
.
Free Radic Biol Med
.
2014
;
72
:
23
-
40
.
9.
Ganz
T
.
Systemic iron homeostasis
.
Physiol Rev
.
2013
;
93
(
4
):
1721
-
1741
.
10.
Nemeth
E
,
Valore
EV
,
Territo
M
,
Schiller
G
,
Lichtenstein
A
,
Ganz
T
.
Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein
.
Blood
.
2003
;
101
(
7
):
2461
-
2463
.
11.
Ganz
T
,
Nemeth
E
.
Iron metabolism: interactions with normal and disordered erythropoiesis
.
Cold Spring Harb Perspect Med
.
2012
;
2
(
5
):
a011668
.
12.
Sahlstedt
L
,
von Bonsdorff
L
,
Ebeling
F
,
Parkkinen
J
,
Juvonen
E
,
Ruutu
T
.
Non-transferrin-bound iron in haematological patients during chemotherapy and conditioning for autologous stem cell transplantation
.
Eur J Haematol
.
2009
;
83
(
5
):
455
-
459
.
13.
Berdoukas
V
,
Nord
A
,
Carson
S
, et al
.
Tissue iron evaluation in chronically transfused children shows significant levels of iron loading at a very young age
.
Am J Hematol
.
2013
;
88
(
11
):
E283
-
E285
.
14.
Koskenkorva-Frank
TS
,
Weiss
G
,
Koppenol
WH
,
Burckhardt
S
.
The complex interplay of iron metabolism, reactive oxygen species, and reactive nitrogen species: insights into the potential of various iron therapies to induce oxidative and nitrosative stress
.
Free Radic Biol Med
.
2013
;
65
:
1174
-
1194
.
15.
Porter
JB
,
Abeysinghe
RD
,
Marshall
L
,
Hider
RC
,
Singh
S
.
Kinetics of removal and reappearance of non-transferrin-bound plasma iron with deferoxamine therapy
.
Blood
.
1996
;
88
(
2
):
705
-
713
.
16.
Pennell
DJ
,
Udelson
JE
,
Arai
AE
, et al;
American Heart Association Committee on Heart Failure and Transplantation of the Council on Clinical Cardiology and Council on Cardiovascular Radiology and Imaging
.
Cardiovascular function and treatment in β-thalassemia major: a consensus statement from the American Heart Association
.
Circulation
.
2013
;
128
(
3
):
281
-
308
.
17.
Claster
S
,
Wood
JC
,
Noetzli
L
, et al
.
Nutritional deficiencies in iron overloaded patients with hemoglobinopathies
.
Am J Hematol
.
2009
;
84
(
6
):
344
-
348
.
18.
Kirk
P
,
Roughton
M
,
Porter
JB
, et al
.
Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major
.
Circulation
.
2009
;
120
(
20
):
1961
-
1968
.
19.
Farmaki
K
,
Tzoumari
I
,
Pappa
C
,
Chouliaras
G
,
Berdoukas
V
.
Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major
.
Br J Haematol
.
2010
;
148
(
3
):
466
-
475
.
20.
Puliyel
M
,
Mainous
AG
III
,
Berdoukas
V
,
Coates
TD
.
Iron toxicity and its possible association with treatment of Cancer: lessons from hemoglobinopathies and rare, transfusion-dependent anemias
.
Free Radic Biol Med
.
2015
;
79
:
343
-
351
.
21.
Chung
WS
,
Lin
CL
,
Lin
CL
,
Kao
CH
.
Thalassaemia and risk of cancer: a population-based cohort study
.
J Epidemiol Community Health
.
2015
;
69
(
11
):
1066
-
1070
.
22.
Kontoghiorghes
GJ
.
The 18th ICOC Proceedings in Athens, Greece: New breakthrough in thalassemia leading to the complete treatment of iron overload and to hundreds of patients achieving and maintaining normal body iron stores. Ethical questions on chelation therapy
.
Hemoglobin
.
2010
;
34
(
3
):
199
-
203
.
23.
Kolnagou
A
,
Kontoghiorghes
GJ
.
New golden era of chelation therapy in thalassaemia: the achievement and maintenance of normal range body iron stores
.
Br J Haematol
.
2010
;
150
(
4
):
489
-
490, author reply 491
.
24.
Coates
TD
,
Wood
JC
.
How we manage iron overload in sickle cell patients
.
Br J Haematol
.
2017
;
177
(
5
):
703
-
716
.
25.
Wood
JC
.
Estimating tissue iron burden: current status and future prospects
.
Br J Haematol
.
2015
;
170
(
1
):
15
-
28
.
26.
Puliyel
M
,
Sposto
R
,
Berdoukas
VA
, et al
.
Ferritin trends do not predict changes in total body iron in patients with transfusional iron overload
.
Am J Hematol
.
2014
;
89
(
4
):
391
-
394
.
27.
Taher
AT
,
Porter
JB
,
Viprakasit
V
, et al
.
Defining serum ferritin thresholds to predict clinically relevant liver iron concentrations for guiding deferasirox therapy when MRI is unavailable in patients with non-transfusion-dependent thalassaemia
.
Br J Haematol
.
2015
;
168
(
2
):
284
-
290
.
28.
Sahlstedt
L
,
Ebeling
F
,
von Bonsdorff
L
,
Parkkinen
J
,
Ruutu
T
.
Non-transferrin-bound iron during allogeneic stem cell transplantation
.
Br J Haematol
.
2001
;
113
(
3
):
836
-
838
.
29.
Porter
JB
,
El-Alfy
M
,
Viprakasit
V
, et al
.
Utility of labile plasma iron and transferrin saturation in addition to serum ferritin as iron overload markers in different underlying anemias before and after deferasirox treatment
.
Eur J Haematol
.
2016
;
96
(
1
):
19
-
26
.
30.
de Swart
L
,
Hendriks
JC
,
van der Vorm
LN
, et al
.
Second international round robin for the quantification of serum non-transferrin-bound iron and labile plasma iron in patients with iron-overload disorders
.
Haematologica
.
2016
;
101
(
1
):
38
-
45
.
31.
Wood
JC
.
Guidelines for quantifying iron overload
.
Hematology (Am Soc Hematol Educ Program)
.
2014
;
2014
(
1
):
210
-
215
.
32.
Noetzli
LJ
,
Papudesi
J
,
Coates
TD
,
Wood
JC
.
Pancreatic iron loading predicts cardiac iron loading in thalassemia major
.
Blood
.
2009
;
114
(
19
):
4021
-
4026
.
33.
Kim
HC
.
Red cell exchange: special focus on sickle cell disease
.
Hematology (Am Soc Hematol Educ Program)
.
2014
;
2014
(
1
):
450
-
456
.
34.
Aydinok
Y
,
Kattamis
A
,
Cappellini
MD
, et al;
HYPERION Investigators
.
Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overload
.
Blood
.
2015
;
125
(
25
):
3868
-
3877
.
35.
Piga
A
,
Longo
F
,
Musallam
KM
, et al
.
Assessment and management of iron overload in β-thalassaemia major patients during the 21st century: a real-life experience from the Italian WEBTHAL project
.
Br J Haematol
.
2013
;
161
(
6
):
872
-
883
.
36.
Berdoukas
V
,
Coates
TD
,
Cabantchik
ZI
.
Iron and oxidative stress in cardiomyopathy in thalassemia
.
Free Radic Biol Med
.
2015
;
88
(
Pt A
):
3
-
9
.
37.
Aydinok
Y
,
Kattamis
A
,
Cappellini
MD
, et al
.
Deferasirox–deferoxamine combination therapy reduces cardiac iron with rapid liver iron removal in patients with severe transfusional iron overload (HYPERION)
.
Blood
.
2013
;
122
(
21
):
2257
.
38.
Voskaridou
E
,
Christoulas
D
,
Terpos
E
.
Successful chelation therapy with the combination of deferasirox and deferiprone in a patient with thalassaemia major and persisting severe iron overload after single-agent chelation therapies
.
Br J Haematol
.
2011
;
154
(
5
):
654
-
656
.
39.
Cappellini
MD
,
Cohen
A
,
Porter
J
,
Taher
A
,
Viprakasit
V
.
Guidlines for management of transfusion dependant thalassemia, vol. 20
.
Strovolos, Nicosia Cyprus
:
Thalassaemia International Federation
;
2014
:
1
-
253
40.
Origa
R
,
Danjou
F
,
Cossa
S
, et al
.
Impact of heart magnetic resonance imaging on chelation choices, compliance with treatment and risk of heart disease in patients with thalassaemia major
.
Br J Haematol
.
2013
;
163
(
3
):
400
-
403
.
You do not currently have access to this content.